On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven’t seen much pumping here. Very little posting for the week. All of the rise was both expected and predicted. Edging higher the rest of today and some recovery going forward to top line data, maybe even back to that .55 peak. In any case, 3 million shares of profit taking and panic selling. All accelerated by news of a drug not even the same target patient population.
The selling was nothing more than market reaction to the Pfizer news. The problem is, the drug is expensive. It’s fine for wealthier countries, but the rest of the world, the other 6 billion people, need a cheaper, effective treatment. Brilacidin is still in the running in dozens of markets.
This will be the gap that never fills, if the top line results are good.
If not, gaps become moot.
Putin doesn’t know and doesn’t care about Brilacidin. He’s making too much money selling Sputnik V, a weak vaccine, at a steep discount to 3rd world nations desperate for anything. What a bunch bullshit.
We’ve discussed this at length last time it came up. The patent was written and filed under the previous CEO. Leo had nothing to do with it. Even IPIX (CTIX) was not held liable by Aruda. All the shares paid to Aruda came from Menon’s shares.
Please enlighten us regarding “patent runways.”
I wanted to sticky Farrell90’s original post, but your reply to it provided both a link and a context. Thanks to both you and Farrell90 for this.
mRNA vaccines have been in development for 20 years and it took a pandemic to finally justify rapidly targeting new viruses followed by safety/efficacy trials.
“If I'm not mistaken B has been around for well over a decade without a serious test of that theory and it has taken a pandemic to justify it.”
The main difference between NNVC and IPIX is that a nanoviricide has never advanced to any clinical study, not even a phase 1. Unspoken in 16 years of preclinical testing is that animals have repeatedly shown inflammation following any application and even topical applications pass through the space between cells and enter the circulatory system.
Brilacidin, on the other hand, has gone through phase 1 and 2 trials both before and after purchase by IPIX/CTIX. Safety issues have been successfully resolved. The question left is whether or not Brilacidin can be an effective antiviral treatment. That question will be answered shortly.
There is no obligation to disclose any data to shareholders except in the event of accidental data release (i.e. 2 people with undisclosed trial knowledge were overheard in a cocktail lounge). Obligation to disclose covers prohibition of selective release (i.e. sharing with only large shareholders so they can front load or liquidate). The only SEC obligation is to not release data to any shareholders or other non-insider parties without sharing with all through a public release.
There is one work around for “public release” (and this is partly my own interpretation), Leo can publicly release data in an SEC filing, and I see no way Leo can justify avoiding reporting results in the next 10Q. That’s because the 10Q includes significant events (my phrasing) and a trial outcome would be significant.
All above said, we need a data release by next Sunday (Halloween) to meet his previous shareholder guidance, or a PR giving a credible explanation why not.
Yeah, sure, I believe you /s
Life and death data is what they looked at. Interim reports for Phase 2 trials rarely examine efficacy. Furthermore, the Russians have nothing to do with examining data as it’s not their trial, they are merely hosts.
I sure get tired of this Putin knows all bullshit.
Key data was not known 6 months ago. That was interim information regarding safety.
Simply not true. Completely fabricated time frame from absolutely nothing.
Colin Powell was fighting cancer when Covid complications added to the demands on his immune system. In his case, vaccination would only have been a hope. According to CNN, “ A source familiar with the matter said Powell had multiple myeloma, a cancer of plasma cells that suppresses the body's immune response.” General Powell is not any type of example for Covid treatment or prevention.
They received 2 billion dollars. They knew they would receive 2 billion. They already had the mRNA vax ready to go, except for the specific protein spike. They received it before human trials, they received it after, what does it matter? They knew they would receive the money same as Moderna already had. Even AZ had a lock because they were 10 years into viral vector technology.
Not Chinese. “Evonik Industries AG is a stock-listed German speciality chemicals company headquartered in Essen, North Rhine-Westphalia, Germany.” They have a very large facility in Vietnam, which may confuse some.
From your source: “ In July, Pfizer got a $1.95 billion deal with the government’s Operation Warp Speed…”
Gosh, I was wrong by half on just Pfizer. My bad. Lol Pfizer got almost 2 billion from the government, not one. I stand corrected.
Moderna and Pfizer already had about $1 billion each for development of a Covid vaccine. The government also mostly handled distribution and public dissemination. The only logistics concerns for the 2 big pharmas were manufacturing, packaging and transport to major hubs for suppliers.
On top of all that (the cherry), mRNA vaccine technology was already 20 years in development.
He can’t get $40 million on a .50 buyout. That violates his own new terms as it would exceed the 5 million share per year cap. On a .50 buyout he could get 2.5 million though. So, yes, we need more details because 2.5 million would be a lot of money for a measly $250 million deal.
It’s not 200 million shares to him or anyone. It’s limited annually to 5 million shares with a maximum cash value of $40 million, or maximum compensation of $20 a share market value. I have no problem with Leo receiving $40 million if my shares are above $20.
There is a legitimate question, though, what targets or benchmarks allow the release of compensation rewards up to 5 million shares or cash equivalent?
The Pfizer vaccine is approved as of last month. Ron Johnson is a know nothing.
Pfizer vaccine is fully approved and over 550 million doses have been administered. It’s no longer experimental.
That’s silly. Try, if you did an assay for your backyard and found out it had gold, and further discover the yield was 18 grams per metric ton. Then you put 100 million into gold extraction technology, but the extraction would take 10 years, would you sell for 1 billion? No. You’d probably sell for 500 million. Let a mine operator make another 500 million over 10 years.
Even lower than my lowball. 115 in 1000 out. That’s a nice return.
Spit balling. The number is likely closer to 200 to 300 million. Early on CTIX/IPIX spent months well above $1 and even substantial time around 2. That was both before and after long periods below $1.
You’re not going to make me go back through 14 years of financials? If someone wats to, they are welcome to and it is vital info for RIO at given license or buyout prices. But, these days I’m just too old and lazy and I think a higher estimate serves better than one that’s too low.
And how might the nebulized Brilacidin be formulated?
Currently Brilacidin powder is mixed with saline. Are you suggesting it’s a simple matter of administrating nebulized IV solution? And even if one did that, how does a nebulized treatment penetrate the heavy congestion that is already suffocating, intubated and ventilated patient? That’s only one issue. There are all kinds of issues with what you propose.
Brilacidin has almost zero absorption through mucosal and gastric tissues. This was established in early trials for colitis and oral mucositis. At the time it was viewed as a benefit because treatment did not include any of the circulatory organs, which means that treatment against oral/digestive diseases does not have to consider impact on the liver or kidneys or the liver processes on the drug.
However, that also means that using Brilacidin to treat respiratory and pulmonary organs cannot be administered orally. It must be administered via injection or inhalation. The drug already has been thoroughly tested administered IV. To be inhaled it would need to go through preclinical work for the best method and formulation (expansive and time consuming).
One doesn’t have to be Dr. DeGrado to know these things.
More important than potential, look at the financials bottom line. Anyone offered a billion cash and securities for lock, stock and barrel, and turns it down for a better offer, is an idiot. There’s nothing wrong with 2.50 a share for a company with $400 million invested and currently trading at 1/12th the price. Otherwise, show me that it’s worth more for a company with one marketable drug in development. I’m all ears.
Agree, but unusual.
Wish I could answer that. However, I think the most likely outcome isn’t a partnership, but a buyout. The decision then would be the new owner. If the trial results show high safety and very mild adverse events, a billion is likely. Otherwise all bets are as good as mine.
Yes, I think reformulation is likely, but it will take lab expertise and money that IPIX doesn’t have. It could be a chimera or some other chemically structural change, or even an aerosol inhaler into the sinuses, there was evidence of sinus absorption for the oral mucositis trials, but those all require Big Pharma money and expertise to further investigate.
It’s already established, oral B won’t work without extensive reformulation.
B can’t be administered for Covid using a capsule/pill. Almost zero gastric absorption. It would never reach the target infection locations. The timed release capsule was used for Upper GI specifically because absorption into the intestinal capillaries was not required.
I refuted it. That’s the difference. You left out half my post, the important half.
Yet, if you’re vaccinated with AZ, Pfizer, J&J or Moderna, you are 3% as likely to be hospitalized. Yet, 40% of America will take a drug that reduces hospitalization only slightly or in MRK’s case 50%. Go figure.
I haven’t said any of those things, ever.
“At shareholder’s expense” is the nature of biopharma startups. Shareholders bear the cost of development and if development is successful shareholders/investors can make a fortune. Or, not. It’s been that way since the world’s first speculative corporation, Dutch East India. It’s always that way.